PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Aliskiren - Hypertension

PAD Profile : Aliskiren - Hypertension Important

Keywords :
essential hypertension, low priority medicine, high blood pressure, NHS England, do not prescribe
Brand Names Include :
Rasilez
Important Information :
NHS England guidance DO NOT ROUTINELY PRESCRIBE

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
03 June 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.

If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.

08 July 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Area Prescribing Committee does not recommend the use of aliskiren in line with NHS England guidance.

Aliskiren will be considered BLACK on the traffic light system.  Prescribers should:

  • NOT initiate aliskiren for any new patient

AND

  • Change patients taking aliskiren to an alternative antihypertensive in line with NICE on the diagnosis and management of hypertension in adults noting that it is important that blood pressure is monitored closely and to consider treatments that may not have previously been used OR
  • Patients should be referred into a specialist for consideration of de-prescribing if appropriate

Associated BNF Codes

02. Cardiovascular System
02.05.05. Renin-angiotensin system drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More